Jovial Wong Speaks at ACI’s Paragraph IV Disputes Conference

Partner Jovial Wong spoke at American Conference Institute’s Paragraph IV Disputes Conference, held in New York from April 29-30. Partners Christopher Essig, Bryce Cooper, Charles Klein, and Brian Nisbet were also in attendance.

This premier forum brings together leading pharmaceutical patent litigators for brand name and generic drug companies to discuss, debate, and analyze the latest trends, judicial rulings and legislative developments affecting Hatch-Waxman litigation.  
 
Jovial participated on a panel titled “Helsinn v. Teva: The Supreme Court Weighs in on the On-Sale Bar and the State of Secret Prior Art,” which discussed the current state of on-sale bar jurisprudence in view of the Supreme Court's monumental decision.

Jovial was a key member of the Helsinn v. Teva team. He routinely assists clients in the fields of pharmaceuticals, biotechnology, medical devices, and other health care products. He also advises clients on matters related to the Hatch-Waxman Act, the BPCIA, and other regulatory issues, as well as in the development of strategic plans to successfully bring generic drug and biosimilar products to market.